Clinical Trial Update: A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications [Phase 3]

View source ↗

Summary

Phase 3 trial comparing two doses of Xeljanz (tofacitinib) versus placebo in rheumatoid arthritis patients on background arthritis medications; results complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• XELJANZ (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2013-01-10